newsfilter
← Latest News
GlobeNewswire·

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by early May 2026 WARREN,